Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mimedx (MDXG) Change in Receivables (2016 - 2026)

Mimedx's Change in Receivables history spans 15 years, with the latest figure at -$28.2 million for Q1 2026.

On a quarterly basis, Change in Receivables fell 491.63% to -$28.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$9.0 million, a 240.66% decrease, with the full-year FY2025 number at $26.4 million, up 934.25% from a year prior.
Change in Receivables hit -$28.2 million in Q1 2026 for Mimedx, down from $887000.0 in the prior quarter.
Over the last five years, Change in Receivables for MDXG hit a ceiling of $11.0 million in Q3 2025 and a floor of -$28.2 million in Q1 2026.
Historically, Change in Receivables has averaged $1.1 million across 5 years, with a median of $2.4 million in 2022.
Biggest five-year swings in Change in Receivables: tumbled 89200.0% in 2022 and later soared 1055.72% in 2025.
Tracing MDXG's Change in Receivables over 5 years: stood at $2.6 million in 2022, then soared by 111.13% to $5.6 million in 2023, then plummeted by 59.61% to $2.3 million in 2024, then tumbled by 60.63% to $887000.0 in 2025, then tumbled by 3280.27% to -$28.2 million in 2026.
Business Quant data shows Change in Receivables for MDXG at -$28.2 million in Q1 2026, $887000.0 in Q4 2025, and $11.0 million in Q3 2025.